Expanded Access Program of PEGASYS® (Peg interferon alpha-2a (40 KD)) in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

Trial Profile

Expanded Access Program of PEGASYS® (Peg interferon alpha-2a (40 KD)) in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Expanded access; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Feb 2017 Last checked against ClinicalTrials.gov record.
    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top